 |
 |
Judith Richards told us in part: > > U.S. Patent No. 5,801,184 describes how purine derivatives, a class of > drug compounds which includes > NeoTherapeutics' lead compound NEOTROFIN(TM) (AIT-082, leteprinim > potassium), can be used to selectively > control ``turning on or off of genes'' for the protein molecules > involved in nerve regeneration. This patent represents a > significant step forward in the treatment of neurodegenerative diseases > utilizing a convenient oral medication to > replace or augment the presence of neurotrophic factors in the brain and > spinal cord. > > Neurotrophic factors are essential for the growth, maturation and > survival of nerve cells. When present in > appropriate concentrations, these factors also protect nerve cells > against damage in stroke, trauma, and many neurodegenerative disorders > including Alzheimer's and PARKINSON'S diseases. These factors are not > produced by the > nervous system in sufficient quantities to be fully effective in those > conditions, and, because neurotrophic factors are > proteins, they cannot be orally administered. These problems are > circumvented by NeoTherapeutics' new patent, > which describes a novel method for treating neurological disorders, > particularly neurodegenerative diseases. > > NeoTherapeutics has developed an orally-active purine derivative, > NEOTROFIN(TM) (AIT-082), which controls > the genetic expression of neurotrophic factors in the nervous system to > treat neurodegenerative diseases. > > Data on the actions of NEOTROFIN(TM) (AIT-082), both in the laboratory > and in clinical trials, will be presented > at the 1998 meeting of the Society for Neuroscience in Los Angeles on > November 10 and 11, 1998. > -- I sure hope some of the movement disorders specialist who treat some of us will be attending this November 1998 meeting. I intend to ask my neuro at my Oct. 98 visit if someone from the Center of Excellence where he practices is going to be in attendance. Trial level II of a drug means it is getting very close to approval and use for the public. How exciting and promising this sounds. Thanks for keeping on top of the latest scientific data/news. Jeanette Fuhr 48/11mos. <[log in to unmask]>